Navigation Links
O2h and Hypoxium Announce an Agreement to Offer Hypoxium's Specialised In Vitro, Cell-Based Oncology Assays via O2h's Biology Affiliate Program

CAMBRIDGE, England, June 25 /PRNewswire/ -- O2h has initiated a networked approach towards being a full service discovery services company at the forefront of drug discovery research. O2h has established a new biology lab on-site in Ahmedabad, India offering physio-chemical and CYP450 assays.

O2h announces the first of its Biology Affiliate Partnership with Hypoxium Ltd. UK. Hypoxium has specialist capabilities in in vitro, cell-based oncology assays which will now be available in a seamless integration with the existing assays performed on-site by O2h.

Sunil Shah, CEO of O2h said "The focus of our biology strategy is to deliver seamless drug discovery via core centres of excellence. We are very happy to bring on board Hypoxium as an affiliate so O2h can now support its clients with oncology focused cell biology assays.

Dan Cowell, CEO of Hypoxium, said: "Working with O2h is an excellent fit with our strategy of supporting drug discovery research in a collaborative manner. It allows O2h clients access to focused cell biology via their existing project manager, yet retains transparent communication with the scientific team responsible for each area."

About O2h

O2h is a 4+ year old discovery services company with project offices in Cambridge, UK and research labs in Ahmedabad, India. Indian operations provide a high level of discovery expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. More details at

About Hypoxium

Based in Cambridge UK, Hypoxium was formed in October 2006 with the sole intention of providing comprehensive, high quality and affordable custom cell biology research services within the oncology therapeutic area. Hypoxium's goal is to provide scientifically driven and industry focused pre-clinical solutions, to assist in the development of novel therapies for oncology. Hypoxium can support projects from proof-of concept through to pre-clinical evaluation of new chemical entities. Since its formation, Hypoxium has attracted a wide range of clients and successfully delivered results that have significantly contributed to their discovery programs. More details at

    O2h Contact: Ekta Ahuja

    Hypoxium Contact: Dan Cowell

SOURCE O2h and Hypoxium
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology
2. Healthy Advice Networks Announces Improved Patient Outcomes in Physicians Offices with Healthy Advice Programs
3. Spherix Announces Termination of Arla License Agreement
4. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
5. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
6. Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)
7. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
8. Dragon Pharma Announces Results of 2009 Annual General Meeting
9. BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests
10. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
11. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):